List of Nextstellis drug patents

Nextstellis is owned by Mayne Pharma.

Nextstellis contains Drospirenone; Estetrol.

Nextstellis has a total of 1 drug patent out of which 0 drug patents have expired.

Nextstellis was authorised for market use on 15 April, 2021.

Nextstellis is available in tablet;oral dosage forms.

Nextstellis can be used as use by females of reproductive potential to prevent pregnancy.

Drug patent challenges can be filed against Nextstellis from April, 2025.

The generics of Nextstellis are possible to be released after 15 April, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Mar, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: April, 2025

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in